XEOMIN is the Newest Botulinum Toxin to Receive FDA Approval

Published: August 9, 2010

A third botulinum toxin type A product has been approved by the FDA. XEOMIN, a product of Merz Pharmaceuticals, earned approval last week for the treatment of adults with cervical dystonia or blepharospasm. The FDA approval of XEOMIN is based on the results of two U.S. clinical trials. It joins Botox and Dysport as botulinum … Continue reading XEOMIN is the Newest Botulinum Toxin to Receive FDA Approval →